Cadrenal Therapeutics, Inc. Common Stock (CVKD) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -3M | -2.57M | -2.36M | -3.03M | -4.65M | -1.79M | -2.2M | -1.53M | -1.84M | -694.45K | -627.78K | -795.31K | -1.41M | -290.22K | 0 |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | 35.42% | -43.52% | -7.08% | -97.86% | -153.15% | -157.86% | -250.64% | -92.28% | -29.98% | -139.29% | - | - | - | - | - |
| Net Income | -2.5M | -3.04M | -2.69M | -3.67M | -3.85M | -4.19M | -2.41M | -2.39M | -1.66M | -1.14M | -1.04M | -1M | -5.17M | -5.01M | -1.03M |
| Depreciation & Amortization | 555 | 555 | 401 | 401 | 5.52K | 407 | 406 | 470 | 597 | 597 | 597 | 597 | 190 | 760 | 506 |
| Stock-Based Compensation | 252.36K | 325.1K | 473.38K | 592.64K | 548.76K | 763.21K | 299.98K | 193.12K | 162.73K | 103.11K | 153.07K | 0 | 286.4K | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | 0 | 0 | 0 | -35 | -106 | -106 | -105 | 24 | 89 | 167.89K | 3.97M | 4.36M | 1.03M |
| Working Capital Changes | -758.6K | 143.37K | -145.23K | 48.44K | -1.36M | 1.63M | -93.67K | 670.25K | -336.31K | 345.88K | 254.92K | 39.21K | -495.69K | 353.75K | 0 |
| Change in Receivables | -370 | 7.7K | 6.25K | 5.63K | 13.49K | 0 | 0 | 8.1K | 8.34K | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 174.15K | 36.54K | -281.48K | -382.79K | -224.07K | 1.01M | -262.69K | 359.14K | 233.05K | 25.66K | 63.52K | -41.43K | -285.33K | 96.68K | 0 |
| Cash from Investing | 0 | 0 | -1.85K | 0 | -3.25K | -6.54K | 0 | 0 | 0 | 0 | -1 | -3.25K | 0 | -1 | 0 |
| Capital Expenditures | 0 | 0 | -1.85K | 0 | -3.25K | -6.54K | 0 | 0 | 0 | -3.25K | -1 | 0 | 0 | 2.28K | 0 |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.3M | 2.72M | 648.36K | 1.26M | 1.97M | 7.45M | 1.53M | 0 | 298 | -12.5K | 6.51M | 0 | 5.41M | 219.72K | 0 |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -250K | 0 | 0 |
| Equity Issued (Net) | 1.3M | 3.1M | 648.36K | 1.32M | 1.97M | 3.62M | 1.53M | 0 | 0 | -12.5K | 6.51M | 0 | 5.41M | 219.72K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | -378.45K | 0 | -63.68K | 0 | 3.84M | 0 | 0 | 298 | 0 | 0 | 0 | 250K | 0 | 0 |
| Net Change in Cash | -1.7M | 147.71K | -1.71M | -1.77M | -2.68M | 5.65M | -673.27K | -1.53M | -1.84M | -706.95K | 5.88M | -798.56K | 4M | -70.5K | 43.44K |
| Free Cash Flow | -3M | -2.57M | -2.36M | -3.03M | -4.65M | -1.8M | -2.2M | -1.53M | -1.84M | -697.7K | -627.78K | -795.31K | -1.41M | -287.94K | 0 |
| FCF Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| FCF Growth % | 35.46% | -42.99% | -7.17% | -97.86% | -153.32% | -157.6% | -250.64% | -92.28% | -29.98% | -142.31% | - | - | - | - | - |
| FCF per Share | -1.25 | -1.29 | -1.15 | -1.54 | -2.52 | -1.18 | -1.99 | -1.43 | -1.72 | -0.80 | -0.72 | -1.02 | -1.81 | -0.37 | - |
| FCF Conversion (FCF/Net Income) | 1.20x | 0.85x | 0.88x | 0.83x | 1.21x | 0.43x | 0.91x | 0.64x | 1.10x | 0.61x | 0.61x | 0.79x | 0.27x | 0.06x | - |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |